A clinical case of B-cell lymphoma in a patient with overlap, primary Sjogren's syndrome and scleredema adultorum of Buschke
Keywords:scleredema adultorum of Buschke, Sjogren’s syndrome, lymphoma, overlap syndrome, clinical case
AbstractThis is a presentation of case report on B-cell lymphoma in a patient with overlapping primary Sjogren's syndrome (PSS) and scleredema adultorum of Buschke. Scleredema adultorum of Buschke (SB) is a rare disorder characterized by a diffuse indurative edema and skin tightening. A putative classification of this disease is based on the etiological factors and encompasses three types: Type 1 is associated with an infectious disease; Type 2 with paraproteinemia; Type 3 – with diabetes mellitus. There are very rare cases involving malignant neoplasms or autoimmune diseases. This clinical case describes a rare combination of SB with an autoimmune disease – PSS. It highlights the importance of studying other SB associations, in particular with autoimmune diseases, to ensure proper management and treatment of these patients. For a 51-year-old patient, the disease onset featured a dense facial edema, dry skin, dry eye syndrome and a feeling of sand in the eyes, subfebrile fever and dense skin formations in the low neckline, mammary glands and interscapular region, which was pathohistologically regarded as scleredema Buschke. Lymphadenopathy, xerophthalmia, sialodenitis, Raynaud's syndrome were revealed, lung damage (alveolitis and bronchiolitis), positive ANA, anti-SSa/La, antiSSb/Ro were diagnosed. Based on this symptom complex, the patient was diagnosed with an overlap syndrome of SB with PSS. The use of combined therapy with methotrexate and methylprednisolone allowed to reduce the disease activity, clinical and laboratory appearance of the disease. However, 9 months after the onset of the first skin symptoms, there was a bulging of the left eye, widespread lymphadenopathy. Histopathological examination revealed the diagnosis of non-Hodgkin B-cell lymphoma. The use of rituximab therapy resulted in a significant regression of the orbital tumor. The relevance of this clinical observation is not only due to the rarity of combined pathology, but also to the need for an early diagnostics of lymphoma developing against the background of PSS, based on the risk factors, which include low levels of C4 and/or C3, enlargement of the parotid salivary glands, cryoglobulinemia, persistent splenomegaly’s systemic activity and lymphadenopathy, since the frequency of this disease is quite high in this patient population.
Lewerenz V, Ruzicka T. Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases. J Eur Acad Dermatol Venereol. 2007 Apr;21(4):560-1. https://doi.org/10.1111/j.1468-3083.2006.01959.x.
Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006 Jun;35(6):355-9. https://doi.org/10.1016/j.semarthrit.2006.01.004.
Manchanda Y, Das S, Sharma VK, Srivastava DN. Scleredema associated with carcinoma of the gall bladder. Br J Dermatol. 2005 Jun;152(6):1373-4. https://doi.org/10.1111/j.1365-2133.2005.06631.x.
Miyagawa S, Dohi K, Tsuruta S, Shirai T. Scleredema of Buschke associated with rheumatoid arthritis and Sjögren's syndrome. Br J Dermatol. 1989 Oct;121(4):517-20. https://doi.org/10.1111/j.1365-2133.1989.tb15522.x.
Alves J, Judas T, Ferreira T, Matos D, Bártolo E. Scleredema associated with Sjögren's syndrome. An Bras Dermatol. 2015 May-Jun;90(3 Suppl 1):81-3. https://doi.org/10.1590/abd1806-4841.20153779.
Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016 Jul 7;2:16047. https://doi.org/10.1038/nrdp.2016.47.
Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum. 2011 Dec;41(3):415-23. https://doi.org/10.1016/j.semarthrit.2011.04.006.
Golovach IYu, Yehudina YeD. Prognostic markers of lymphoma in primary Sjogren’s syndrome. Practical oncology. 2019;2(3):9-23. https://doi.org/10.22141/2663-32220.127.116.119.186472.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020 Jan;79(1):3-18. https://doi.org/10.1136/annrheumdis-2019-216114.
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ. 2012 Jun 14;344:e3821. https://doi.org/10.1136/bmj.e3821.
Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum. 2004 Apr;50(4):1262-9. https://doi.org/10.1002/art.20176.
Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005 Nov 14;165(20):2337-44. https://doi.org/10.1001/archinte.165.20.2337.
Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016 Jun;95(25):e3766. https://doi.org/10.1097/md.0000000000003766.
Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford). 2010 Mar;49(3):571-7. https://doi.org/10.1093/rheumatology/kep404.
How to Cite
Copyright (c) 2020 Ye.D. Yehudina, S.А. Trypilka, S.Kh. Ter-Vartanіan
This work is licensed under a Creative Commons Attribution 4.0 International License.